Protein modification of living cells using sortase
AssigneeWhitehead Institute for Biomedical Research
InventorsLee Kim Swee, Hidde L. Ploegh
Life of this patent
Estimating the term…
Abstract
Non-genetically engineered mammalian cells modified by sortase-mediated conjugation of an agent thereto are provided. Methods of conjugating agents to nongenetically engineered mammalian cells using sortase are provided. Methods of using the cells, e.g. a method of modulating an immune response of a subject to an entity of interest, a method of neutralizing a substance in the body of a subject, a method of treating a subject in need of treatment for deficiency of a protein, and a method of treating a subject in need of treatment for a disease, are provided.
Claims17
A human cell having a binding moiety or therapeutic agent linked thereto via a sortase recognition sequence, wherein the binding moiety or therapeutic agent is linked to an endogenous, non-genetically engineered protein expressed by the human cell, and wherein the human cell has not been genetically engineered to express a polypeptide comprising a sortase recognition sequence, wherein the binding moiety or therapeutic agent comprises an immune checkpoint inhibitor.
A mammalian cell having a binding moiety or therapeutic agent linked thereto via a sortase recognition sequence, wherein the binding moiety or therapeutic agent is linked to an endogenous, non-genetically engineered protein expressed by the mammalian cell, and wherein the binding moiety or therapeutic agent comprises an immune checkpoint inhibitor.
Dependencies are inferred from the claim text.